Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + melatonin
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy of metformin and melatonin that demonstrates synergistic effects on glucose metabolism, insulin sensitivity, and metabolic parameters. Metformin is a widely used anti-diabetic drug that improves insulin sensitivity and reduces hepatic glucose production, while melatonin is a hormone that regulates sleep-wake cycles and modulates glucose metabolism. When combined, they show enhanced benefits for treating metabolic disorders, particularly in obesity-associated type 2 diabetes.
02
Targets
ND1 (Mitochondrial electron transport chain complex I)MTNR1A (MT1)NQO2 (Ribosyldihydronicotinamide dehydrogenase [quinone])MTNR1B (Melatonin Receptor 2)
Beyond the preview
Go deeper on metformin + melatonin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + melatonin.